Pacific Biosciences Of California (PACB) Change in Receivables (2010 - 2026)

Pacific Biosciences Of California's Change in Receivables history runs 17 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 247.97% year-over-year to -$6.1 million in Q1 2026; TTM through Mar 2026 was -$2.3 million, a 273.6% decrease from a year earlier, with the FY2025 full-year figure at $7.9 million, up 187.16% from the prior year.
• Change in Receivables slipped to -$6.1 million in Q1 2026 per PACB's latest filing, from $4.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $10.8 million in Q1 2023 and bottomed at -$6.3 million in Q1 2024.
• The 5-year median for Change in Receivables is -$794000.0 (2022), against an average of $300529.4.
• Across the five-year window, Change in Receivables tumbled 1445.76% in 2022 and jumped 359.92% in 2025, its largest moves.
• Year by year, Change in Receivables stood at -$4.0 million in 2022, then surged by 254.38% to $6.1 million in 2023, then tumbled by 130.33% to -$1.9 million in 2024, then jumped by 359.92% to $4.8 million in 2025, then slumped by 226.2% to -$6.1 million in 2026.
• Per Business Quant, the three latest PACB Change in Receivables figures stand at -$6.1 million (Q1 2026), $4.8 million (Q4 2025), and -$1.6 million (Q3 2025).